Literature DB >> 46247

The release of four mediators of immediate hypersensitivity from human leukemic basophils.

R A Lewis, E J Goetzl, S I Wasserman, F H Valone, R H Rubin, K F Austen.   

Abstract

The availability of a patient with basophilic leukemia manifesting 75 to 90% mature basophils permitted the use of a cell concentration sufficient to generate and release mediators upon interaction with a calcium ionophore in quantities adequate for their physiocochemical characterization. The mediators were defined in terms of their physicochemical characteristics: slow reacting substance of anaphylaxis (SRS-A) by purification through silicic acid chromatography and inactivation by arylsulfatase; eosinophil chemotactic factor of anaphylaxis (ECF-A) by its gel filtration through Sephadex G-25 and inactivation by subtilisin and not trypsin; and platelet-activating factor (PAF) by its inherent binding to albumin. Both ECF-A and histamine were present in their preformed state, and for histamine it was possible to establish that the concentration per cell was comparable to that of normal human basophils. Dibutyryl cyclic AMP suppressed release of histamine and SRS-A, indicating that their availability was under a control similar to that observed with normal cells subjected to immunologic activation. The demonstration that a suspension of leukemic human basophils contained the preformed mediators, histamine and ECF-A, and generated SRS-A and PAF for release along with histamine and ECF-A, after activation with a calcium ionophore, establishes that a single cell type can serve as a source of the four recognized mediators of immediate-type hypersensitivity.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 46247

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  Immunopathology of the lung: a review.

Authors:  K J Johnson; W E Chapman; P A Ward
Journal:  Am J Pathol       Date:  1979-06       Impact factor: 4.307

2.  Cold urticaria. Recognition and characterization of a neutrophil chemotactic factor which appears in serum during experimental cold challenge.

Authors:  S I Wasserman; N A Soter; D M Center; K F Austen
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

3.  Augmented local anaphylaxis at sites of delayed hypersensitivity skin reactions.

Authors:  D J Pearson; G Taylor
Journal:  Immunology       Date:  1977-07       Impact factor: 7.397

4.  Activation of rabbit platelets by platelet-activating factor derived from IgE-sensitized basophils. Characteristics of the aggregation and its dissociation from secretion.

Authors:  P M Henson
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

5.  Isolation of human eosinophil phospholipase D.

Authors:  L A Kater; E J Goetzl; K F Austen
Journal:  J Clin Invest       Date:  1976-05       Impact factor: 14.808

6.  Precursor role of arachidonic acid in release of slow reacting substance from rat basophilic leukemia cells.

Authors:  B A Jakschik; S Falkenhein; C W Parker
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

Review 7.  [Phagocytosis--a central mechanism in inflammatory reaction (author's transl)].

Authors:  J F Kapp
Journal:  Klin Wochenschr       Date:  1978-11-01

8.  Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils.

Authors:  G Camussi; M Aglietta; R Coda; F Bussolino; W Piacibello; C Tetta
Journal:  Immunology       Date:  1981-02       Impact factor: 7.397

9.  Identification and partial characterization of an exercise-induced neutrophil chemotactic factor in bronchial asthma.

Authors:  T H Lee; L Nagy; T Nagakura; M J Walport; A B Kay
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

10.  Antigen-induced eosinophil chemotactic factor (ECF) release by human leukocytes.

Authors:  B M Czarnetzki; W König; L M Lichtenstein
Journal:  Inflammation       Date:  1976-03       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.